Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Norfolk Southern Corporation (NSC) vs Twist Bioscience Corp (TWST) Price & Performance

Norfolk Southern CorporationTrade
Twist Bioscience CorpTrade

Price performance (Past 24H)

Key statistics

Norfolk Southern Corporation vs Twist Bioscience Corp — how do they compare? Norfolk Southern Corporation trades at $334.86 (market cap $75.15B), while Twist Bioscience Corp trades at $124.63 (market cap $7.72B). The key difference: Norfolk Southern Corporation is far larger — about 9.7× Twist Bioscience Corp's market cap, and Norfolk Southern Corporation pays a 1.61% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.

NSCTWST
Market Cap
$75.15B$7.72B
Sector
TechnologyHealth
52-Week High
$350.66$124.88
52-Week Low
$272.35$24.16
Enterprise Value
$90.70B$7.65B
Dividend Yield
1.61%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Norfolk Southern Corporation

Norfolk Southern (NSC) trades at $332.82, down 0.34% on the day, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 earnings of $3.52 per share, beating estimates, driven by record revenue and volume growth. Valuation ratios like P/E of 28.55 and P/S of 5.99 indicate a premium, while profitability remains solid with a net income margin of 21.02% and ROE of 16.97%. Recent news highlights merger developments with Union Pacific and institutional interest.

Outlook is cautiously optimistic due to earnings momentum and industry tailwinds, but risks include high fuel costs, merger execution uncertainties, and premium valuation. Analysts give a mixed consensus with 43.75% buy ratings and a $369.67 price target, suggesting modest upside potential from current levels amid competitive and operational headwinds.

Twist Bioscience Corp

Twist Bioscience (TWST) trades at $123.76, down 0.9% on the day, with a bullish technical signal from moving averages but bearish oscillators. Revenue growth is strong, with 2025 revenue at $376.57 million, though the company remains unprofitable with a net income margin of -31.66%. Recent news highlights an upsized $300 million public offering and an analyst upgrade, contributing to positive sentiment.

The outlook is mixed: robust revenue growth and high analyst buy ratings (78.57%) support upside potential, but persistent losses, negative cash flow, and high valuation ratios pose significant risks. Investors should weigh the growth trajectory against the path to profitability and cash burn concerns.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Norfolk Southern Corporation

Norfolk Southern Corporation is a major North American railroad company operating one of the largest freight rail networks in the eastern United States. The company transports a diverse range of commodities, including coal, intermodal containers, and various industrial products. NSC is a critical link in the nation's supply chain, providing efficient, long-haul transportation services to and from ports and industrial centers.

Read more on NSC

About Twist Bioscience Corp

Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.

Read more on TWST